Recent News
Sep 8, 2021
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

South San Francisco, CA, September 8, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...

Aug 10, 2021
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights

South San Francisco, CA, August 10, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...

Stock Info
NASDAQSTSA